Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma

British Journal of Cancer

Volumn 87, Issue 6, 2002, Pages 591-599

  Österlund, Pia ^a   Orpana, A ^a   Elomaa, I ^a   Repo, H ^a   Joensuu, H ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

5 fluorouracil; Carmofur; Colorectal cancer; Cytokine; Raltitrexed; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN; CARMOFUR; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 6; INTERLEUKIN 8; RALTITREXED; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY TEMPERATURE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DRUG INFUSION; FATIGUE; FEMALE; FEVER; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADENOCARCINOMA; ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; C-REACTIVE PROTEIN; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FATIGUE; FEMALE; FEVER; FLUOROURACIL; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIVER NEOPLASMS; LONGITUDINAL STUDIES; LUNG NEOPLASMS; MALE; MIDDLE AGED; QUINAZOLINES; THIOPHENES; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037048308     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600520     Document Type: Article

References (34)

1. Andre T, Bensmaine MA, Louvet C, Francois E, Lucas V, Desseigne F, Beerblock K, Bouche O, Carola E, Merrouche Y, Morvan F, Dupont-Andre G, de Gramont A (1999a) Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 17: 3560-3508
2. Andre T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A (1999b) CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 35: 1343-1347
3. Anonymous (1992) Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864-874
4. Anonymous (1999) Drug-company decision to end cancer trial. Lancet 354: 1045
5. Bleiberg H, de Gramont A (1998) Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer. Semin Oncol 25: 32-39
6. Bone RC (1996) Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 125: 680-687
7. Chiche D, Pico JL, Bernaudin JF, Chouaib S, Wollman E, Arnoux A, Denizot Y, Nitenberg G (1993) Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNF-alpha and PAF. Eur Cytokine Netw 4: 147-151
8. Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. J Clin Oncol 16: 2943-2952
9. Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G (1996) Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. 'Tomudex' Colorectal Cancer Study Group. Ann Oncol 7: 961-965
10. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815
11. de Vries MR, Borel Rinkes IH, Swaak AJ, Hack CE, Van De Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Eggermont AM (1999) Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases. Eur J Clin Invest 29: 553-560
12. de Vries MR, Rinkes IH, van de Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Vahrmeijer AL, Eggermont AM (1998) Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Rec Results Cancer Res 147: 107-119
13. Garcia-Vargas JE, Sahmoud T, Smith MP, Green S (1999) Qualitative and chronological assessment of toxicities during treatment with raltitrexed ('tomudex') in 861 patients: Implications for patient management. Eur J Cancer 35:72 (abstract 222)
14. Gluckman JC, Canque B, Chapuis F, Rosenzwajg M (1997) In vitro generation of human dendritic cells and cell therapy. Cytok Cell Molecul Ther 3: 187-196
15. Lindner P, Fjalling M, Hafstrom L, Kierulff-Nielsen H, Mattsson J, Schersten T, Rizell M, Naredi P (1999) Isolated hepatic perfusion with extracorporeal oxygenation using hyperthermia, tumour necrosis factor alpha and melphalan. Eur J Surg Oncol 25: 179-185
16. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J (1998) Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Experiment Immunol 113: 401-406
17. Maughan TS, James RD, Kerr D, McArdle C, Ledermann JA, Seymour M, Johnston C, Stephens R (1999) Preliminary Results of a Multicentre Randomised Trial Comparing 3 Chemotherapy Regimens (de Gramont, Lokich and Raltitrexed) in Metastatic Colorectal Cancer. Proc Am Soc Clin Oncol 18: 262a (abstract 1007)
18. May LT, Ghrayeb J, Santhanam U, Tatter SB, Sthoeger Z, Helfgott DC, Chiorazzi N, Grieninger G, Sehgal PB (1988) Synthesis and secretion of multiple forms of beta 2-interferon/B-cell differentiation factor 2/hepatocyte-stimulating factor by human fibroblasts and monocytes. J Biol Chem 263: 7760-7766
19. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riche F, Leleu G, Arbibe L, Mignon A, Delpech M, Dhainaut JF (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282: 561-568
20. Mishra A, Doyle NA, Martin WJC (2000) Bleomycin-mediated pulmonary toxicity: evidence for a p53-mediated response. Am J Respir Cell Mol Biol 22: 543-549
21. Miyauchi M, Yamamoto NMatsumotoM, Shishikura T, Hyakutake K (2000) [Comparative clinical study on 5-FU concentrations for oral HCFU and i.v, 5-FU]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 27: 1011-1014
22. Oka Y, Naomoto Y, Yasuoka Y, Hatano H, Haisa M, Tanaka N, Orita K (1997) Apoptosis in cultured human colon cancer cells induced by combined treatments with 5-fluorouracil, tumor necrosis factor-alpha and interferon-alpha. Jpn J Clin Oncol 27: 231-235
23. Osterlund P, Elomaa I, Virkkunen P, Joensuu H (2001) A phase I study of Raltitrexed (Tomudex) combined with Carmofur in Metastatic Colorectal Cancer. Ontology (Basel) 61: 113-119
24. Osterlund P, Elomaa I, Virkkunen P, Ruotsalainen T, Joensuu H (2000) A Phase II Study Of Ralitirexed ('tomudex') Combined With Carmofur in Metastatic CRC. Proc Am Soc Clin Oncol 19: 282a (abstract 1104)
25. Pazdur R, Vincent M (1997) Raltitrexed (Tomudex®) versus 5-fluorouracil and leucovorin (5-FU + LV) in patients with advanced colorectal cancer (ACC): results of a randomized, multicenter North American trial. Proc Am Soc Clin Oncol 16: 228a (abstract 801)
26. Saltz L, Cox J, Blanke C, Rosen L, Fehrenbacher L, Moore M, Maroun J, Ackland S, Locker P, Pirotta N, Elfring G, Miller L (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914
27. Scheid C, Young R, McDermott R, Fitzsimmons L, Scarffe JH, Stern PL (1994) Immune function of patients receiving recombinant human interleukin-6 (IL-6) in a phase I clinical study: induction of C-reactive protein and IgE and inhibition of natural killer and lymphokine-activated killer cell activity. Cancer Immunol Immunother 38: 119-126
28. Sleijfer S, Vujaskovic Z, Limburg PC, Schraffordt Koops H, Mulder NH (1998) Induction of tumor necrosis factor-alpha as a cause of bleomycin-related toxicity. Cancer 82: 970-974
29. Takala A, Jousela I, Olkkola KT, Jansson SE (1999) Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. Clin Sci (Colch) 96: 287-295
30. Takala A, Lahdevirta J, Jansson SE, Vapalahti O, Orpana A, Karonen SL, Repo H (2000) Systemic inflammation in hemorrhagic fever with renal syndrome correlates with hypotension and thrombocytopenia but not with renal injury. J Infect Dis 181: 1964-1970
31. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, Suzuki T, Okada M (1997) The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 57: 1335-1343
32. Tomita A, Fuchino Y, Otsuka K, Shinohara T, Tanaka SN, Umeno T, Ikeda S (1998) Clinical effects of exogenous/endogenous TNF therapy on metastatic lesions of 34 colorectal cancer patients. Anticancer Res 18: 3937-3939
33. Watanabe N, Niitsu Y, Yamauchi N, Ohtsuka Y, Sone H, Neda H, Maeda M, Urushizaki I (1988) Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs. Immunopharmacol Immunotoxicol 10: 117-127
34. Volk HD, Reinke P, Krausch D, Zuckermann H, Asadullah K, Muller JM, Docke WD, Kox WJ (1996) Monocyte deactivation-rationale for a new therapeutic strategy in sepsis. Intensive Care Med 22: S474-S481